

ANTARES PHARMA, INC.  
Form 8-K  
August 20, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 15, 2013**

**ANTARES PHARMA, INC.**

(Exact name of registrant specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-32302**  
(Commission  
File Number)

**41-1350192**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: ANTARES PHARMA, INC. - Form 8-K

**100 Princeton South, Suite 300, Ewing, NJ**  
(Address of principal executive offices)

**08628**  
(Zip Code)

**Registrant's telephone, including area code: (609) 359-3020**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On August 15, 2013, Kaushik Dave PhD, our Executive Vice President of Product Development, resigned effective September 15, 2013. Dr. Dave will be assuming the position of Chief Executive Officer at a biotechnology company and, if needed, has agreed to act as a consultant to Antares. Our Vice President of Clinical Development and our Vice President of Regulatory Affairs and Quality will assume Dr. Dave's project management responsibilities.

Dr. Dave's Employment Agreement, dated March 3, 2008 (the "Employment Agreement"), will be terminated upon the effective date of his resignation. The Employment Agreement was previously filed with the Securities and Exchange Commission by the Company as exhibit 10.18 to its Annual Report on Form 10-K for the year ended December 31, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTARES PHARMA, INC.

Date: August 19, 2013

By: /s/ Paul K. Wotton  
Name: Dr. Paul K. Wotton  
Title: President and Chief Executive Officer